Literature DB >> 23707452

The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer?

Brian J Linder1, Stephen A Boorjian, John C Cheville, William R Sukov, Prabin Thapa, Robert F Tarrell, Igor Frank.   

Abstract

PURPOSE: We investigated the association of histological reclassification during pathology re-review of radical cystectomy specimens with clinicopathological outcomes in patients initially classified with urothelial carcinoma.
MATERIALS AND METHODS: We identified 1,211 patients initially diagnosed with urothelial carcinoma at radical cystectomy between 1980 and 2005. All pathological specimens were re-reviewed by a urological pathologist. Survival was estimated using the Kaplan-Meier method and compared with the log rank test.
RESULTS: Of 1,211 cases previously recorded as pure urothelial carcinoma 406 (33%) were reclassified as variant histology. The most common variant histologies identified were squamous in 151 patients (37%) and micropapillary in 62 (15%). Variant histology on re-review was associated with a higher rate of extravesical disease (71%) than urothelial carcinoma at initial diagnosis (52%) or pure urothelial carcinoma on re-review (42%, p<0.0001). Median postoperative followup was 11.1 years, during which 976 patients died, including 564 of bladder cancer. Notably, reclassification resulted in significant stratification of 10-year cancer specific survival, which was 50% in patients with pure urothelial carcinoma after re-review, 47% in those with urothelial carcinoma on initial interpretation and 42% in those with variant histology on re-review (p=0.03). Ten-year overall survival in patients with urothelial carcinoma on re-review, urothelial carcinoma at initial interpretation and variant histology on re-review was 29%, 27% and 24%, respectively (p=0.04).
CONCLUSIONS: Pathological re-review of radical cystectomy specimens identified variant histology in a third of patients. These variants are associated with a high rate of locally advanced disease, which may impact the noted rates of cancer specific and overall survival. Thus, it is critical to be aware of re-review status when interpreting outcomes from historical data sets and stratifying risk.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CSS; OS; RC; UC; cancer specific survival; carcinoma; diagnosis; overall survival; pathology; radical cystectomy; urinary bladder; urothelial carcinoma; urothelium

Mesh:

Year:  2013        PMID: 23707452     DOI: 10.1016/j.juro.2013.05.040

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.

Authors:  Henning Reis; Rene Serrette; Jennifer Posada; Vincent Lu; Ying-Bei Chen; Anuradha Gopalan; Samson W Fine; Satish K Tickoo; Sahussapont J Sirintrapun; Gopa Iyer; Samuel A Funt; Min Yuen Teo; Jonathan E Rosenberg; Dean F Bajorin; Guido Dalbagni; Bernard H Bochner; David B Solit; Victor E Reuter; Hikmat A Al-Ahmadie
Journal:  Am J Surg Pathol       Date:  2019-07       Impact factor: 6.394

2.  Adjuvant chemotherapy in bladder cancer patients with histological variants: time to change the approach?

Authors:  Luca Afferi; Stefania Zamboni; Philipp Baumeister; Livio Mordasini; Agostino Mattei; Marco Moschini
Journal:  Transl Androl Urol       Date:  2019-07

Review 3.  [Predictive biomarkers in bladder cancer].

Authors:  H Reis; T Szarvas
Journal:  Pathologe       Date:  2019-12       Impact factor: 1.011

Review 4.  [Predictive biomarkers in oncologic uropathology].

Authors:  H Reis; T Szarvas; V Grünwald
Journal:  Pathologe       Date:  2019-05       Impact factor: 1.011

Review 5.  Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.

Authors:  Manju Aron
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

6.  Trends in the use of neoadjuvant chemotherapy for bladder cancer with nonurothelial variant histology: An analysis of the National Cancer Database.

Authors:  Campbell M Grant; Richard Amdur; Michael J Whalen
Journal:  Indian J Urol       Date:  2019 Oct-Dec

7.  Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy.

Authors:  Jae-Hoon Chung; Chung-Un Lee; Dong-Hyeon Lee; Wan Song
Journal:  Biomedicines       Date:  2022-04-15

Review 8.  Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.

Authors:  Joshua J Meeks; Hikmat Al-Ahmadie; Bishoy M Faltas; John A Taylor; Thomas W Flaig; David J DeGraff; Emil Christensen; Benjamin L Woolbright; David J McConkey; Lars Dyrskjøt
Journal:  Nat Rev Urol       Date:  2020-03-31       Impact factor: 14.432

Review 9.  Molecular Pathology of Urothelial Carcinoma.

Authors:  Hikmat Al-Ahmadie; George J Netto
Journal:  Surg Pathol Clin       Date:  2021-09

10.  Neoadjuvant cisplatin-based chemotherapy in "primary" and "secondary" muscle-invasive bladder cancer-is it a surrogate for molecular subtypes?

Authors:  Tibor Szarvas; Csilla Olah; Henning Reis
Journal:  Transl Cancer Res       Date:  2019-03       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.